Early trial shows promise of cholesterol-lowering injection
Heart patients who need to be cognizant of their cholesterol levels may find it helpful and cost-efficient to buy Canadian Lipitor.
Heart patients who need to be cognizant of their cholesterol levels may find it helpful and cost-efficient to buy Canadian Lipitor. Drug manufacturers are constantly developing new medications to approach high cholesterol. One injection created by Amgen, Inc. is showing some early promise in preliminary human tests.
In order to assess the performance of the monoclonal antibody AMG145, researchers enrolled 56 healthy individuals who were not taking medication into their experiment. Subjects received either one of five different doses of the drug or a placebo.
AMG145 targets PCSK9, a protein that prevents the liver from removing low density lipoproteins (bad cholesterol) from the blood.
Results showed that over the course of 85 to 113 days, patients who received AMG145 expressed less PCSK9, had lower levels of bad cholesterol and maintained levels of good cholesterol. Furthermore, these effects intensified with higher doses of the drug. The highest amount of AMG145 reduced bad cholesterol 64 percent lower than those who had placebos, as presented at the American Heart Association's Scientific Sessions 2011.
"PCSK9 is the first target in lipid metabolism to be inhibited using a monoclonal antibody, and it appears to be a promising way to lower bad cholesterol," said researcher Clapton Dias, Ph.D.
Further studies are needed to verify these effects, including trials on individuals who are taking statins.
|
